Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.
rafeykeith

Lew Fidler Says He Found A Kidney Donor | Observer

CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia - Yahoo Finance

(Photo: William Alatriste/NYC Council) After months of searching, former Councilman Lew Fidler announced this afternoon that he found a kidney donor. Mr. Fidler, a Brooklyn Democrat, had been actively seeking a donor since last September.
For the original version including any supplementary images or video, visit http://observer.com/2015/04/former-city-councilman-announces-he-has-found-kidney-donor/

Amazon to Carry Complete Natural Products, Available to Millions of Consumers

Both types of hyperlipoproteinia are associated with an increased risk of acute and chronic pancreatitis that is severe and potentially life-threatening. The treatment goal for patients is to reduce their triglycerides, chylomicrons and VLDL to reduce the risk of severe clinical events. About MBX-8025 MBX-8025 is a potent and selective agonist of PPAR, a nuclear receptor important for lipid transport, storage and metabolism in liver and muscle.MBX-8025 has shown favorable effects on lipid and metabolic parameters in a Phase 2 study in patients with mixed dyslipidemia.Treatment effects observed include lowering of LDL-C with selective depletion of pro-atherogenic dense LDL-C particles, decreases in triglycerides and increases in high density lipoprotein, as well as decreases in hsCRP, a biomarker of cardiovascular inflammation.CymaBay is in the process of initiating a pilot clinical study evaluating the activity of MBX-8025 in patients with homozygous familial hypercholesterolemia. About CymaBay CymaBay Therapeutics, Inc. ( CBAY ) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in multiple Phase 2 gout studies. In gout patients, arhalofenate is intended to prevent painful flares in joints while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the signs and symptoms of gout go here now and the hyperuricemia that is the root cause of the disease. CymaBay's second product candidate, MBX-8025 is a potent, selective, orally active PPAR agonist.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cymabay-therapeutics-announces-u-orphan-120000421.html

The North Korean leader also has a family history of heart attacks, the doctor said. Both his grandfather Kim Il Sung and father Kim Jong Il reportedly died from acute myocardial infarctions. Additionally, if Kim suffers from high blood pressure or diabetes, his risk of heart attack increases to 20 times the average. In 2014 when Kim was absent from public events for 40 days and later reappeared with a cane, some analysts said the injury was the result of gout while others said it was due to a broken ankle, Sky News reported . Pyongyang eventually admitted Kim had suffered from "discomfort" but without providing details. One South Korean doctor said based on Kim's weight it is possible his "cholesterol levels are...off the charts," and that Kim is ailing from "metabolic syndrome, a hodgepodge of pre-diabetes symptoms such as high blood pressure, hyperlipidemia and obesity." Earlier this month Sky News reported Kim appeared on North Korean television with a bandage tied around his right wrist.
For the original version including any supplementary images or video, visit http://www.upi.com/Top_News/World-News/2015/04/22/Kim-Jong-Uns-weight-gain-places-him-at-risk-of-heart-attack-experts-say/2391429708065/

Kim Jong Un struggles with rapid weight gain - UPI.com

Notable Deaths of 2015 Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in multiple Phase 2 gout studies. In gout patients, arhalofenate is intended to prevent painful flares in joints while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. CymaBay's second product candidate, MBX-8025 is a potent, selective, orally active PPAR agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has initiated a pilot study of MBX-8025 in patients with homozygous familial hypercholesterolemia.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cymabay-therapeutics-announces-initiation-phase-120000483.html

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia - Yahoo Finance

boca raton fl (PRWEB) April 24, 2015 Complete Natural Products, a brand that offers solution-specific supplements for individuals dealing with significant pain and other health issues, will now be available on Amazon.com, the worlds largest online marketplace. The brands high-impact products take a somewhat different approach to pain management and other health concerns, combining many check it out ingredients in a synergistic approach to help reduce inflammation, decrease pain, dissolve stones, balance the bodys pH levels and improve digestive function. The results are highly effective supplements that leverage the power of multiple ingredients to help people dealing with conditions affecting the kidneys, liver, prostate, urinary tract, joints, gallbladder and more. We are thrilled to announce that our supplements are now available on Amazon, a go-to source for health and nutrition products for consumers across the United States and beyond, said Scot Poole, owner of Complete Natural Products. We look forward to the impact our products will have on this platform, as there is now the potential for millions of more individuals to discover just how effective and helpful our products can be. This is great news for our brand as we continue to expand our line throughout the U.S.
For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/04/prweb12674365.htm

New WVU Study Combines Arthritis Meds to Better Alleviate Pain

Improving the quality of life for arthritis sufferers is a cause that unexpectedly hit close to home for Kinsey. The disease is so commonplace that its often brushed aside, Kinsey said, despite so many people suffering or not knowing they suffer from it. Until recently, Kinsey wasnt aware his family had experienced arthritis pain. On the day the National Institute of Health reviewed Kinseys grant, he was home sick with his first bout of gout a form of arthritis that cause severe pain and swelling of the joints. The Arthritis Foundation estimates at least 6.1 million Americans have experienced such an attack. Such numbers highlight the need for new treatments to combat those effects.
For the original version including any supplementary images or video, visit http://www.newswise.com/articles/view/633092/?sc=rsmn

Don't be the product, buy the product!

Schweinderl